DD

Devarsh Dixitbhai Shah

Active Director Director DIN 11577252
DIN 11577252 First appointment Feb 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Total affiliations 2 Since Feb 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Devarsh Dixitbhai Shah

Data last updated:

Devarsh Dixitbhai Shah is a Director at Vegam Overseas Private Limited (since 2026) and Director at Yashosiddhi Pharma Private Limited (since 2026).

DIN 11577252
Primary Designation Director
First Appointment 27 Feb 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Vegam Overseas Private Limited U46599GJ2026PTC183663
Director15 Sep 20262026Active
Yashosiddhi Pharma Private Limited U46497GJ2026PTC174307
Director27 Feb 20262026Active

Board colleagues of Devarsh Dixitbhai Shah

Directorship timeline

Open interactive timeline →
Yashosiddhi Pharma Private Limited
Vegam Overseas Private Limited
Premium access

Shareholding and investment profile for Devarsh Dixitbhai Shah

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Devarsh Dixitbhai Shah

Devarsh Dixitbhai Shah currently holds 2 directorships: Vegam Overseas Private Limited (Director, since 15 Sep 2026); Yashosiddhi Pharma Private Limited (Director, since 27 Feb 2026).

Devarsh Dixitbhai Shah was first appointed on 27 Feb 2026 as Director at Yashosiddhi Pharma Private Limited.

The current boards of Devarsh Dixitbhai Shah's companies include Pruthvivant Pareshkantilal Shah (Vegam Overseas Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available